PRENETICS

Enhancing
Life Through Science

Latest Updates

2023.06.26
Insighta Brand Video
Video introducing the launch of Insighta, dedicated to saving lives through the power of early cancer detection.
View
2023.06.26
Analyst Presentation, June 2023
Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture “Insighta” for Breakthrough Multi-Cancer Early Detection Screening
View

Prenetics, a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment.
Prevention
Fast-growing health-conscious consumer base
Early Detection
Detecting multi-cancer at the early stages, significantly improving the chances of treatment
Treatment
Targeted therapy for cancer patients

Prenetics, a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment.

Prevention

At CircleDNA, we recognize that every individual has unique health needs and goals, and we are dedicated to empowering them with the tools and knowledge to take control of their health.

Early Detection

Insighta, a landmark Joint Venture between Prenetics (NASDAQ: PRE), and renowned scientist, Prof. Dennis Lo, aims to revolutionize multi-cancer early detection. Backed by world-class science from Prof. Lo, robust capital resources of US$100m from Prenetics, and led by successful entrepreneur Danny Yeung, the joint venture is poised to transform cancer screening. Insighta plans to introduce Presight for lung and liver cancers in 2025, and to expand with Presight One for 10+ cancers in 2027. Insighta presents an unprecedented opportunity to save lives and bolster Hong Kong's standing as a global hub for life sciences innovation.

Treatment

With the acquisition of ACT Genomics, we can now offer comprehensive cancer treatments worldwide, bringing us closer to our goal of detecting and treating cancer as early as possible.
Prenetics, a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Our prevention arm, CircleDNA, uses whole exome sequencing to offer the world's most comprehensive consumer DNA test. Insighta, our $200 million joint venture with renowned scientist Prof. Dennis Lo, underscores our unwavering commitment to saving lives through pioneering multi-cancer early detection technologies. Insighta plans to introduce Presight for lung and liver cancers in 2025, and to expand with Presight One for 10+ cancers in 2027. Lastly, ACT Genomics, our treatment unit, is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Each of Prenetics' units synergistically enhances our global impact on health, truly embodying our commitment to enhancing life through science.